GenVec says TNFerade may fight esophageal cancer

By Elaine Rigoli

Tampa, Fla., May 23 - GenVec, Inc. said its investigational cancer drug TNFerade demonstrated potential utility in treating patients with esophageal cancer.

This data was gathered from updated survival information from a clinical study, showing evidence of esophageal tumor response to TNFerade when delivered by intratumoral injection once per week for five weeks with concurrent chemoradiation (cisplatin, 5-FU, radiation), the company said in a news release.

The study compared the safety and efficacy of four different doses of TNFerade in 24 patients with locally advanced resectable esophageal cancer prior to surgery.

Overall patient survival for all dose levels is currently 83% at 18 months and 64% at 24 months, which compares favorably to six comparable recent studies showing one-year survival rates of 52% and five comparable recent studies showing two-year survival of 33%.

GenVec, based in Gaithersburg, Md., is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.